Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Ozempic Was Used by Two Million Medicare Part D Enrollees in 2024, Up from Fewer Than 150,000 in 2019 Semaglutide, the GLP-1 drug branded as Ozempic, Rybelsus, and Wegovy, was the most used GLP-1 in 2024
Medication access: About 67.1% of the cohort accessed only one GLP-1, while 25.9% accessed two distinct GLP-1 medications, and 7% accessed three or more
doi: 10.1210/en.2002-0068 114 KimSJWinterKNianCTsuneokaMKodaYMcIntoshCH
Retatrutide is a more recently developed triple agonist peptide, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously
US$ 20.68
US$ 23.37
US$ 20.81
US$ 27.96
